Clinical trials: Docetaxel, completed
Breast Neoplasms
Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose
For the specific patient population studied receiving 5-Fluorouracil, epirubicin and cyclophosphamide - Docetaxel sequence (cumulative dose <300 mg / m2), using a cryoprotection has never been assessed.
- Trial name
- BANQUISE (NCT02283983)
- Testing
- mittens and booties, cooling helmet
- Where
- 10 sites in France
- Volunteers
- 319 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Breast Cancer
Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Triple-negative breast cancer (TNBC) has a relatively bad prognosis whereas there is no standard regimen. Some data showed that platins could improve the efficacy of advance TNBC.
- Trial name
- NCT01150513
- Testing
- EC-T, TP
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer
Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2.
- Trial name
- NCT00232479
- Testing
- trastuzumab, docetaxel and carboplatin in dose dense regimen
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Miami
Neoplasms
A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients
The primary objective of this study is to determine the dose of aflibercept to be further studied in combination with docetaxel in Japanese cancer patients.
- Trial name
- NCT00545246
- Testing
- aflibercept (AVE0005), docetaxel
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Sanofi
Breast Cancer
Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy drugs kill cancer cells more directly.
- Trial name
- NCT00365417
- Testing
- Bevacizumab, Doxorubicin, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- NSABP Foundation Inc
Lung Cancer
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, pemetrexed disodium, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00301808
- Testing
- Cisplatin, Docetaxel, Pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer
Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075374
- Testing
- docetaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Nasopharyngeal Squamous Cell Carcinoma, Toxicity Due to Radiotherapy
GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China
The present study is a randomized, control, phase II study of locally advanced nasopharyngeal carcinoma (NPC) in Northwest China treated with Gemcitabine plus cisplatin regimen (GP) or Docetaxel plus cisplatin regimen (TP)…
- Trial name
- NCT01596868
- Testing
- gemcitabine and cisplatin, docetaxel and cisplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Air Force Military Medical University, China
Salivary Gland Tumors, Head and Neck Cancer
Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
This is a non-randomized, phase II, open label study of postoperative current chemoradiotherapy for high-risk malignant salivary gland tumors of head and neck.The primary purpose of this study is to evaluate the efficacy and…
- Trial name
- NCT02776163
- Testing
- Nedaplatin, Docetaxel, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Locally Advanced Esophageal Squamous Cell Carcinoma
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
The main purpose of this study is to evaluate the safety of the neoadjuvant therapy, nivolumab with CF (5-FU, CDDP) or nivolumab with DCF (5-FU, CDDP, DTX), for locally advanced esophageal carcinoma.
- Trial name
- NCT03914443
- Testing
- Nivolumab, 5-FU, CDDP
- Where
- Japan
- Volunteers
- 37 people
- Sponsor
- National Cancer Center, Japan
Prostate Cancer
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Primary Objective: To assess effectiveness of prophylactic treatment of hematological complications (grade ≥ 3 neutropenia) resulting from cabazitaxel treatment for 21 days after treatment initiation.
- Trial name
- PROSPECTA (NCT01649635)
- Testing
- CABAZITAXEL (XRP6258), Prednisone, Ciprofloxacin
- Where
- 6 sites in Brazil
- Volunteers
- 45 people
- Sponsor
- Sanofi
Lung Cancer
Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227708
- Testing
- docetaxel, quality-of-life assessment
- Where
- 9 sites in France, Switzerland and 1 more
- Volunteers
- 58 people
- Sponsor
- UNICANCER
Cholangiocarcinoma Cancer, Gallbladder Cancer
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
To assess the feasibility of administering induction chemotherapy with gemcitabine and docetaxel followed by concurrent radiation and continuous infusion 5FU and consolidation gemcitabine/docetaxel chemotherapy.
- Conditions
- Cholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer
- Trial name
- NCT00660699
- Testing
- Gemcitabine, Docetaxel, Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5.
- Trial name
- NT-NAP-102-1 (NCT04880863)
- Testing
- NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- NeoTX Therapeutics Ltd.
Prostate Cancer
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
This study is for patients with cancer of the prostate gland that has metastasized or spread outside the prostate to other parts of the body.
- Trial name
- NCT00327340
- Testing
- custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Achieve Life Sciences
Prostate Cancer
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or…
- Trial name
- NCT00286793
- Testing
- AT-101
- Where
- 13 sites in United States
- Volunteers
- 76 people
- Sponsor
- Ascenta Therapeutics
Non Small Cell Lung Cancer
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
This is a pilot single institution study of DRibble vaccination + GM-CSF in patients with stage IIIB or IV NSCLC who have undergone 0-1 chemotherapy regimens for metastatic disease.
- Trial name
- DRibble (NCT00850785)
- Testing
- DRibble vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
In the China extension study, Chinese participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed…
- Trial name
- NCT03933449
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Where
- 23 sites in China
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
The purpose of this study is to describe the rate of 3-year progression free survival in men with recurrent PSA-only disease after prostatectomy, who receive combined apalutamide (ARN-509) and standard ADT with salvage radiation…
- Trial name
- NCT03311555
- Testing
- Apalutamide, Androgen deprivation, Salvage radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Andrew J. Armstrong, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.